Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors (Q38248682)

1 September 2017

3 references

30 January 2021

4 February 2021

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors (English)

1 reference

dipeptidyl peptidase-4 inhibitors

1 September 2017

1 reference

1 reference

30 January 2021

1 reference

4 February 2021

0 references

2

Daniel J Drucker

2 references

25216328

1 September 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1

Erin E Mulvihill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

12 September 2014

1 reference

25216328

1 September 2017

1 December 2014

2 references

30 January 2021

4 February 2021

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

30 January 2021

4 February 2021

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

992-1019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

Direct evidence for the binding of rat liver DPP IV to collagen in vitro.

1 June 2020

cites work

1 reference

12 December 2020

The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes

1 reference

12 December 2020

Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.

1 reference

12 December 2020

Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis

1 reference

12 December 2020

Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion

1 reference

12 December 2020

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

1 reference

12 December 2020

The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist

1 reference

12 December 2020

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences

1 reference

12 December 2020

Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats

1 reference

12 December 2020

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans

1 reference

12 December 2020

Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 reference

12 December 2020

Physiology and pathophysiology of incretins in the kidney

1 reference

12 December 2020

Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.

1 reference

12 December 2020

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

1 reference

12 December 2020

The enteroinsular axis in dipeptidyl peptidase IV-negative rats

1 reference

12 December 2020

Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism

1 reference

12 December 2020

Enhanced ovalbumin-induced airway inflammation in CD26−/−mice

1 reference

12 December 2020

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

1 reference

12 December 2020

Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26)

1 reference

12 December 2020

Unraveling oxyntomodulin, GLP1's enigmatic brother

1 reference

12 December 2020

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

12 December 2020

Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y.

1 reference

12 December 2020

Action and therapeutic potential of oxyntomodulin

1 reference

12 December 2020

Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs

1 reference

12 December 2020

Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

1 reference

12 December 2020

Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease

1 reference

12 December 2020

Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV).

1 reference

12 December 2020

Antibody-induced modulation of CD26 surface expression

1 reference

12 December 2020

Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells

1 reference

12 December 2020

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

1 reference

12 December 2020

Crystallization and preliminary X-ray study of human dipeptidyl peptidase IV (DPPIV).

1 reference

12 December 2020

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

12 December 2020

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26.

1 reference

12 December 2020

Therapeutic potential of neuropeptide Y (NPY) receptor ligands.

1 reference

12 December 2020

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

1 reference

12 December 2020

Cardiovascular actions of incretin-based therapies

1 reference

12 December 2020

A peptidomics strategy to elucidate the proteolytic pathways that inactivate peptide hormones

1 reference

12 December 2020

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

1 reference

12 December 2020

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

1 reference

12 December 2020

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

1 reference

12 December 2020

Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides.

1 reference

12 December 2020

On the origin of serum CD26 and its altered concentration in cancer patients.

1 reference

12 December 2020

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

1 reference

12 December 2020

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

1 reference

12 December 2020

Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma

1 reference

12 December 2020

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

12 December 2020

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.

1 reference

12 December 2020

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

12 December 2020

Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4.

1 reference

12 December 2020

Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes

1 reference

12 December 2020

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

12 December 2020

N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.

1 reference

12 December 2020

CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.

1 reference

12 December 2020

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

1 reference

12 December 2020

PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

1 reference

12 December 2020

Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling

1 reference

12 December 2020

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

1 reference

12 December 2020

Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes

1 reference

12 December 2020

The TATA-less, GC-rich porcine dipeptidylpeptidase IV (DPPIV) promoter shows bidirectional activity

1 reference

12 December 2020

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

1 reference

12 December 2020

Differential regional metabolism of glucagon in anesthetized pigs

1 reference

12 December 2020

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

12 December 2020

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy

1 reference

12 December 2020

Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways

1 reference

12 December 2020

CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response

1 reference

12 December 2020

Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV

1 reference

12 December 2020

A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation

1 reference

12 December 2020

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

1 reference

12 December 2020

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

1 reference

12 December 2020

Peptidase substrates via global peptide profiling

1 reference

12 December 2020

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

12 December 2020

1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside blocks the apical biosynthetic pathway in polarized HT-29 cells.

1 reference

12 December 2020

Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor

1 reference

12 December 2020

Comparative studies of the sugar chains of aminopeptidase N and dipeptidylpeptidase IV purified from rat kidney brush-border membrane

1 reference

12 December 2020

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

1 reference

12 December 2020

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide

1 reference

12 December 2020

Amino acid sequences of three bombesin-like peptides from canine intestine extracts.

1 reference

12 December 2020

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

1 reference

12 December 2020

Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats

1 reference

12 December 2020

Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy

1 reference

12 December 2020

Pharmacology, physiology, and mechanisms of incretin hormone action

1 reference

12 December 2020

Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases

1 reference

12 December 2020

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

1 reference

12 December 2020

Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review).

1 reference

12 December 2020

Hydrolysis of amino acidβ-naphthylamides by aminopeptidases in human parotid saliva and human serum

1 reference

12 December 2020

Sitagliptin exerts an antinflammatory action

1 reference

12 December 2020

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease

1 reference

12 December 2020

Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes

1 reference

12 December 2020

Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter

1 reference

12 December 2020

Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo

1 reference

12 December 2020

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

1 reference

12 December 2020

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

12 December 2020

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

1 reference

12 December 2020

Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model.

1 reference

12 December 2020

Colony stimulating factors and myeloid cell biology in health and disease.

1 reference

12 December 2020

Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.

1 reference

12 December 2020

Quantification of intact and truncated stromal cell-derived factor-1α in circulation by immunoaffinity enrichment and tandem mass spectrometry

1 reference

12 December 2020

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form

1 reference

12 December 2020

Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study

1 reference

12 December 2020

Domain‐Specific N‐Glycosylation of the Membrane Glycoprotein Dipeptidylpeptidase IV (CD26) Influences its Subcellular Trafficking, Biological Stability, Enzyme Activity and Protein Folding

1 reference

12 December 2020

PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.

1 reference

12 December 2020

Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions

1 reference

12 December 2020

Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs

1 reference

12 December 2020

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.

1 reference

12 December 2020

Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform

1 reference

12 December 2020

An active-site mutation (Gly633-->Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum

1 reference

12 December 2020

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

1 reference

12 December 2020

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

1 reference

12 December 2020

Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α

1 reference

12 December 2020

Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene

1 reference

12 December 2020

Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells

1 reference

12 December 2020

Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.

1 reference

12 December 2020

Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

CD26, let it cut or cut it down.

1 reference

12 December 2020

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

1 reference

12 December 2020

Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice

1 reference

12 December 2020

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

1 reference

12 December 2020

Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis.

1 reference

12 December 2020

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

1 reference

12 December 2020

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

1 reference

12 December 2020

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

1 reference

12 December 2020

Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study

1 reference

12 December 2020

Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence

1 reference

12 December 2020

CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7.

1 reference

12 December 2020

Identification of hydrophobic residues critical for DPP-IV dimerization.

1 reference

12 December 2020

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

1 reference

12 December 2020

Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

12 December 2020

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

1 reference

12 December 2020

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

1 reference

12 December 2020

Gut hormone PYY(3-36) physiologically inhibits food intake

1 reference

12 December 2020

Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.

1 reference

12 December 2020

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

1 reference

12 December 2020

Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage

1 reference

12 December 2020

Soluble DPP4 originates in part from bone marrow cells and not from the kidney.

1 reference

12 December 2020

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.

1 reference

12 December 2020

CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity

1 reference

12 December 2020

DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

1 reference

12 December 2020

Cardiovascular biology of the incretin system

1 reference

12 December 2020

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

1 reference

12 December 2020

Bombesin-like peptides: of ligands and receptors

1 reference

12 December 2020

Emerging roles of proteases in tumour suppression

1 reference

12 December 2020

Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands

1 reference

12 December 2020

Regulation of the gene for human dipeptidyl peptidase IV by hepatocyte nuclear factor 1 alpha

1 reference

12 December 2020

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

1 reference

12 December 2020

The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding

1 reference

12 December 2020

Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2.

1 reference

12 December 2020

Metabolism of glucagon by dipeptidyl peptidase IV (CD26).

1 reference

12 December 2020

Seprase-dPPIV association and prolyl peptidase and gelatinase activities of the protease complex

1 reference

12 December 2020

Peptidomic analysis of blood plasma after in vivo treatment with protease inhibitors--a proof of concept study

1 reference

12 December 2020

Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene

1 reference

12 December 2020

One site mutation disrupts dimer formation in human DPP-IV proteins

1 reference

12 December 2020

Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding

1 reference

12 December 2020

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

1 reference

12 December 2020

Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

12 December 2020

Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome

1 reference

12 December 2020

Direct association of adenosine deaminase with a T cell activation antigen, CD26

1 reference

12 December 2020

Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus

1 reference

12 December 2020

GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations

1 reference

12 December 2020

Circulating CD26 is negatively associated with inflammation in human and experimental arthritis

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

12 December 2020

What do we know about the secretion and degradation of incretin hormones?

1 reference

12 December 2020

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

1 reference

12 December 2020

CD26 is essential for normal G-CSF–induced progenitor cell mobilization as determined by CD26−/− mice

1 reference

12 December 2020

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

1 reference

12 December 2020

Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells

1 reference

12 December 2020

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro

1 reference

12 December 2020

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

12 December 2020

Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis

1 reference

12 December 2020

Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY

1 reference

12 December 2020

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans

1 reference

12 December 2020

Structure of the mouse dipeptidyl peptidase IV (CD26) gene

1 reference

12 December 2020

Cloning and functional expression of the T cell activation antigen CD26.

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice

1 reference

12 December 2020

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

12 December 2020

Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects

1 reference

12 December 2020

Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis

1 reference

12 December 2020

Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.

1 reference

12 December 2020

Epitope analysis of the rat dipeptidyl peptidase IV monoclonal antibody 6A3 that blocks pericellular fibronectin-mediated cancer cell adhesion

1 reference

12 December 2020

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

1 reference

12 December 2020

Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis.

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

1 reference

12 December 2020

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

1 reference

12 December 2020

Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

1 reference

12 December 2020

Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1

1 reference

12 December 2020

Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV

1 reference

12 December 2020

Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

1 reference

12 December 2020

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

12 December 2020

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers

1 reference

12 December 2020

Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface

1 reference

12 December 2020

Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction

1 reference

12 December 2020

Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality

1 reference

12 December 2020

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

12 December 2020

Molecular characterization of dipeptidyl peptidase activity in serum

1 reference

12 December 2020

Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor

1 reference

12 December 2020

Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats

1 reference

12 December 2020

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

12 December 2020

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

1 reference

12 December 2020

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice

1 reference

12 December 2020

Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

1 reference

12 December 2020

Identifiers

DOI

10.1210/ER.2014-1035

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

25216328

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25216328%20AND%20SRC:MED&resulttype=core&format=json